Several hundred new jobs will be created in the next three to five years when Allergan Inc. opens a new research and development facility in New Jersey, according to an announcement from Gov. Chris Christie, who said the company is expected to inject about $12 million in private investment into the state's economy.
"Our aggressive efforts to promote economic growth and foster job creation and investment in our state are delivering results for New Jerseyans," Christie said in a press release issued Monday. "Allergan's decision to choose New Jersey is just the latest indication that the Jersey comeback has begun."
Allergan is a technology-driven, multispecialty health care company with 10,000 employees in more than 100 countries. It was established more than 60 years ago as an eye-care company; today, Allergan also focuses on neurosciences, medical aesthetics, medical dermatology, obesity intervention and urologics. The company has an array of pharmaceuticals, biologics, medical devices, over-the-counter consumer products and state-of-the-art resources in research and development, manufacturing and safety surveillance.
Christie met with Allergan officials in September to discuss the company's expansion plans and showcase New Jersey's strengths as a destination for their facility.
"Expanding our already vibrant health care sector is a critical component of the Christie administration's economic growth agenda," said Lt. Gov. Kim Guadagno. "The life sciences are a cornerstone of New Jersey's economy, providing high-quality jobs for our residents and fostering innovations that impact the lives of people throughout the world."
On Wednesday, the board of the Economic Development Authority is set to vote on a Business Employment Incentive Program grant, worth up to $17 million over 10 years, to encourage Allergan to open a facility in New Jersey. The company has not yet identified a specific location for the new facility.
Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.View Comment Policy